Animal Housing
JUMISC Animal Housing Unit provides services to companies and research groups in multiple preclinical trials. This unit develops designs and performs preclinical validation on demand. It counts with professionals qualified to design, monitor and validate any type of biomedical study. An important feature of this unit is the possibility to house, maintain and supervise large animals for preclinical validation. This service also counts with a dilated experience in the handling and care of minipigs and what its use in preclinical studies implies.
It has a floor net area of 2.865 m2. It is equipped with spacious rooms to house experimentation animals depending on its specie characteristics (age, sex, weight, breed) and the research projects they are assigned to. Among the equipment and facilities are: rooms for the maintenance of large animals, rooms for the maintenance of small ruminants, rooms for the maintenance of birds, barrier-zone for the maintenance of rodents in SPF conditions, an operating room integrated within the barrier area, multipurpose rooms for the maintenance of rodents and lagomorphs, a room for the reception and handling of the animals, quarantine rooms for pre-experimental processes, a room for small procedures and cures and rooms for the preparation of large animals prior to the surgical area.
Among the services that the Unit develops, we highlight the following:
- U22-S01 Housing and care of animal models.
- U22-S02 In vivo experimental design/consultancy for preclinical procedures.
- U22-S03 In vivo Toxicological studies in rodent and non-rodent species.
- U22-S04 In vivo Biocompatibility studies of medical devices in rodent and non-rodent species.
- U22-S05 PK/PD studies in rodent and non-rodent species.
- U22-S06 In vivo Safety and efficacy studies of nanomaterials, biomaterials and new drugs in rodent and non-rodent species.
- U22-S07 Development of animal models of disease in large animals.
- U22-S08 Dosing of test substances and non-clinical specimen drawing in rodent and non-rodent species.
Customer benefits
All rooms and facilities included in the unit are certified with ISO-9001 and Good Laboratory Practices (GLP), strict quality standards that allow the production of highly accurate results.
In this way, preclinical, security and efficacy studies in animal models can be performed in compliance with the strict guidelines of the regulation agencies, ensuring reliability and traceability of all tests and results performed in its different services.
In addition, this team has been certified by the Spanish Agency of Drugs and Health Products (AEMPS) for studies of “Dosification of problem substances and non-clinical samples”, “Biocompatibility studies of health products”, “In vivo toxicity”, “Tolerance” and “Pharmacodynamics”. All these certifications allow to carry out studies to verify the efficacy, security and biocompatibility of nanotechnological development.
Target customer
The offered services can be of interest to a large number of companies, including the following:
Pharmaceutical and biotechnological companies: Companies that carry out preclinical and clinical studies for the development of drugs, therapies and biotechnological products and require animals to test the efficacy and security of their products.
Academic Researchers: Professors, researchers and students from academic institutions who need access to animals to conduct scientific research in areas like biology, medicine, behaviour, etc.
Medical Institutions: Hospitals, clinics and medical research centres that conduct studies to understand human diseases and develop medical treatments, including preclinical trials on animals.
Medical devices companies: Medical devices manufacturers who need to test the security and efficacy of their products on animals before commercialization.
Regulatory agencies: Government agencies in charge of regulating and monitoring security and efficacy of medical and pharmaceutical products, which may require data from animal studies to support products approval.
Food and agriculture companies: Companies that develop food and agricultural techniques may need to conduct animal studies to evaluate food security, the effects of additives, efficacy in agricultural products, etc.
Additional information
Selected publications:
- Peiro JL, et al. Fetal Endoscopic Third Ventriculostomy Is Technically Feasible in Prenatally Induced Hydrocephalus Ovine Model. Neurosurgery 2023; Jun 1;92(6): 1303-1311.
- Blanco-Blázquez V, et al. Swine Models of Aneurysmal Diseases for Training and Research. J Vis Exp 2022; Mar 23: 181.
- Lucas-Cava V, et al. Prostatic artery occlusion versus prostatic artery embolisation for the management of benign prostatic hyperplasia: early results in a canine model. British Journal of Radiology 2022; 95: 1136.
- Soria F, et al. Assessment of a Coated Mitomycin-Releasing Biodegradable Ureteral Stent as an Adjuvant Therapy in Upper Urothelial Carcinoma: A Comparative In Vitro Study. Polymers 2022; 14: 3059.
- Campos JL, et al. Popliteal Vascular Lymph Node Resection in the Rabbit Hindlimb for Secondary Lymphedema Induction. J Vis Exp 2022; Nov 30: 189.
- de la Cruz JE, et al. Biodegradable ureteral stents: in vitro assessment of the degradation rates of braided synthetic polymers and copolymers. Am J Clin Exp Urol 2022; Feb 15;10(1) :1-12.
- Crisóstomo V, et al. The epicardial delivery of cardiosphere derived cells or their extracellular vesicles is safe but of limited value in experimental infarction. Sci Rep 2021; Nov 12;11(1): 22155.
- Ballestín A, et al. A Pre-clinical Rat Model for the Study of Ischemia-reperfusion Injury in Reconstructive Microsurgery. J Vis Exp 2019; Nov 8: 153.
- López E, et al. Identification of very early inflammatory markers in a porcine myocardial infarction model. BMC Vet Res 2019; Mar 12;15(1): 91.
- Enciso S, et al. Validation of a model of intensive training in digestive laparoscopic surgery. Cir Esp 2016; Feb;94(2):70-6.
- Crisostomo V, et al. Allogeneic cardiac stem cell administration for acute myocardial infarction. Expert Rev Cardiovasc Ther 2015; 13(3): 285-99.